OKYO is fully funded through the Phase 3 NEPTUNE trial initiation and completion, removing near-term dilution risk. The key catalyst is trial enrollment updates in H2 2026. Monitor for patient enrollment milestones and any data readouts.
Price Chart
Executive Summary
OKYO Pharma filed its annual report and provided a corporate update highlighting a $22M capital raise, $20.6M cash position, and plans to initiate the Phase 3 NEPTUNE trial for urcosimod in H2 2026. The company is fully funded through the trial's completion, reducing near-term dilution risk.
Key Facts
- Raised approximately $22M in February 2026 public offering
- Cash and cash equivalents of $20.6M as of March 2026
- Phase 3 NEPTUNE trial for urcosimod planned for H2 2026
- FDA Type D meeting supports potential single-trial approval pathway
Financial Impact
Cash position of $20.6M fully funds Phase 3 trial completion; $22M capital raise strengthens balance sheet.
Risk Factors
- Clinical trial failure risk for urcosimod
- No approved products or revenue
- Potential future dilution if additional capital needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers